Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217616 - 217616
Published: March 1, 2025
Language: Английский
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: June 4, 2024
Abstract Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type tumor have remained grim long time. Currently, it extremely challenging to prevent or detect early enough effective treatment because patients rarely exhibit symptoms there are no reliable indicators detection. Most advanced spreading that difficult treat, treatments like chemotherapy radiotherapy can only slightly prolong their life by few months. Immunotherapy has revolutionized pancreatic cancer, yet its effectiveness limited tumor's immunosuppressive hard-to-reach microenvironment. First, article explains microenvironment highlights wide range immunotherapy options, including therapies involving oncolytic viruses, modified T cells (T-cell receptor [TCR]-engineered chimeric antigen [CAR] T-cell therapy), CAR natural killer cell therapy, cytokine-induced cells, immune checkpoint inhibitors, immunomodulators, vaccines, strategies targeting myeloid in context contemporary knowledge future trends. Lastly, discusses main challenges ahead immunotherapy.
Language: Английский
Citations
36
Advanced Drug Delivery Reviews, Journal Year: 2024, Volume and Issue: 206, P. 115190 - 115190
Published: Feb. 1, 2024
mRNA-based vaccines are emerging as a promising alternative to standard cancer treatments and the conventional vaccines. Moreover, FDA-approval of three nucleic acid based therapeutics (Onpattro, BNT162b2 mRNA-1273) has further increased interest trust on this type therapeutics. In order achieve significant therapeutic efficacy, mRNA needs from drug delivery system. last years, several platforms have been explored, being lipid nanoparticles (LNPs) most well characterized studied. A better understanding how operate (both itself system) will help improve their efficacy safety. review, we provide an overview what mode action highlight advantages challenges different that under investigation.
Language: Английский
Citations
22
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: May 22, 2024
Abstract Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance toxicity still remain. Due the advancement of immuno-oncology, an increasing number novel immunoregulatory targets mechanisms are being revealed, with relevant therapies promising improve clinical immunotherapy in foreseeable future. Therefore, comprehending larger picture is important. In this review, we analyze summarize current landscape preclinical translational mechanistic research, drug development, trials that brought about next-generation pharmacological anti-cancer agents candidates beyond classical immune checkpoint inhibitors. Along further clarification immunobiology advances antibody engineering, targeting additional inhibitory checkpoints, including LAG-3, TIM-3, TIGIT, CD47, B7 family members becoming important part research discovery, as structurally functionally optimized agonists co-stimulatory molecules T cells. Exemplified bispecific cell engagers, newly emerging bi-specific multi-specific antibodies can provide considerable benefits. Next-generation also include epigenetic drugs cytokine-based therapeutics. Cell therapies, vaccines, oncolytic viruses not covered review. This comprehensive review might aid development fastest possible adoption effective immuno-oncology modalities for benefit patients.
Language: Английский
Citations
20
Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217079 - 217079
Published: June 25, 2024
Language: Английский
Citations
17
Med, Journal Year: 2025, Volume and Issue: 6(1), P. 100562 - 100562
Published: Jan. 1, 2025
Language: Английский
Citations
6
Advanced Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 10, 2025
Abstract Cancer immunotherapy, which leverages immune system components to treat malignancies, has emerged as a cornerstone of contemporary therapeutic strategies. Yet, critical concerns about the efficacy and safety cancer immunotherapies remain formidable. Nanotechnology, especially polymeric nanoparticles (PNPs), offers unparalleled flexibility in manipulation‐from chemical composition physical properties precision control nanoassemblies. PNPs provide an optimal platform amplify potency minimize systematic toxicity broad spectrum immunotherapeutic modalities. In this comprehensive review, basics polymer chemistry, state‐of‐the‐art designs from physicochemical standpoint for encompassing vaccines, situ vaccination, adoptive T‐cell therapies, tumor‐infiltrating cell‐targeted antibodies, cytokine therapies are delineated. Each immunotherapy necessitates distinctively tailored design strategies nanoplatforms. The extensive applications PNPs, investigation their mechanisms action enhanced particularly focused on. profiles clinical research progress discussed. Additionally, forthcoming developments emergent trends nano‐immunotherapeutics poised transform treatment paradigms into clinics explored.
Language: Английский
Citations
3
Trends in Pharmacological Sciences, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological cancers. However, achieving comparable success in solid tumors remains challenging. Factors contributing to these limitations include scarcity of tumor-specific antigens (TSAs), insufficient CAR-T infiltration, and immunosuppressive tumor microenvironment (TME). Vaccine-based strategies are emerging as potential approaches address challenges, enhancing expansion, persistence, antitumor efficacy. In this review, we explore diverse vaccine modalities, including mRNA, peptide, viral vector, dendritic (DC)-based vaccines, their roles augmenting responses. Special focus is given recent clinical advancements combining mRNA-based vaccines with genitourinary addition, discuss crucial considerations optimizing dosing, scheduling, delivery maximize synergy, aiming refine combination strategy improve efficacy safety.
Language: Английский
Citations
2
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 9, 2025
Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity known used, they often fail to achieve satisfactory long-term patient outcomes survival. Recently, immunotherapy has shown success patients by harnessing important interactions between immune system cancer. However, many these therapies lead frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, severe cases, fatalities. New approaches like intratumoral immunotherapy, characterized reduced effects, cost, systemic toxicity, offer promising prospects for future applications clinical oncology. In context locally metastatic cancer, combining diverse immunotherapeutic other targeting multiple cancer hallmarks appears crucial. Such combination hold promise improving survival promoting a sustained response. This review aims provide overview approaches, specifically focusing on administration drugs cancers. It also explores integration modalities maximize Additionally, summarizes recent advances discusses novel outlining directions field.
Language: Английский
Citations
2
ACS Nano, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 17, 2025
Since their inception in the early 1960s, development and use of nanoscale materials have progressed tremendously, roles diverse fields ranging from human health to energy electronics are undeniable. The application nanotechnology inventions has revolutionized many aspects everyday life including various medical applications specifically drug delivery systems, maximizing therapeutic efficacy contained drugs by means bioavailability enhancement or minimization adverse effects. In this review, we utilize CAS Content Collection, a vast repository scientific information extracted journal patent publications, analyze trends nanoscience research relevant an effort provide comprehensive detailed picture field. We examine publication landscape area insights into current knowledge advances developments. review major classes nanosized routes, targeted diseases. outline most discussed concepts assess advantages nanocarriers. objective is broad overview evolving regarding challenges, evaluate growth opportunities. merit stems extensive, wide-ranging coverage up-to-date information, allowing unmatched breadth analysis in-depth insights.
Language: Английский
Citations
2
Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 92 - 92
Published: Jan. 19, 2025
Human papillomavirus (HPV) is a major global health issue and recognized as the leading cause of cervical cancer. While prophylactic vaccination programs have led to substantial reductions in both HPV infection rates cancer incidence, considerable burdens HPV-related diseases persist, particularly developing countries with inadequate vaccine coverage uptake. The development therapeutic vaccines for represents an emerging strategy that has potential bolster fight against Unlike current designed prevent new infections, aim eradicate or treat existing well HPV-associated precancers cancers. This review focuses on clinical studies involving cancer, specifically three key areas: treatment intraepithelial neoplasia; combination without chemotherapy, radiotherapy, immune checkpoint inhibitors; role prophylaxis following completion treatment. Currently, there are no approved worldwide; however, active progress being made research using multiple platforms such peptides, proteins, DNA, RNA, bacterial vectors, viral cell-based, each offering relative advantages limitations delivering antigens generating targeted responses. We outline preferred parameters, including indications, target populations, safety considerations, efficacy immunization strategies. Lastly, we emphasize currently under could be important tool fighting
Language: Английский
Citations
2